A recent study demonstrated that BRD9 levels are in fact elevated in ovarian cancer, and that inhibition sensitizes ovarian cancer to PARP inhibition and cisplatin therapy through regulation of the DNA damage response machinery—a frequently disrupted pathway in ovarian cancer.113, 114. This evidence concerns the gene BRD9 and ovarian carcinoma.